Latest news
FDA Approves First Orexin-Targeting Drug for Narcolepsy Type 1 - Sleep ReviewSleep Review · Wed, 05 Aug 2026 22:18:00 GMTApnimed’s IPO Bags $192M for What Could Become the First Oral Sleep Apnea Drug - MedCity NewsMedCity News · Sun, 02 Aug 2026 22:42:36 GMTApnimed, Developer of Oral Therapies for Obstructive Sleep Apnea, Files for Nasdaq Global Select Market IPO - TradingViewTradingView · Fri, 31 Jul 2026 20:09:00 GMT